Investing Profile

Jakob Loven

InvestorVC
Managing Partner at Nextech Invest Ltd.
Photo of Jakob Loven, Managing Partner at Nextech Invest Ltd.

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
University of Cambridge Network
361 CONNECTIONS
Third Rock Ventures Network
54 CONNECTIONS
AstraZeneca Network
29 CONNECTIONS
Swedish Armed Forces Network
13 CONNECTIONS
cb
Nextech Invest Ltd. Managing Partner
$100K - $5.0M
$1.5M
11
CompanyStageDateRound SizeTotal Raised
Boundless Bio
Series CMay 2023$100M
Series BApr 2021$110M
$250M
Co-investors: Jonathan Lim (SignalFire), Jonathan Lim (ARCH Venture Partners), Zach Scheiner (RA Capital Management)
Flare Therapeutics
Series BMar 2023$120M
$290M
Co-investors: Abbie Celniker (Third Rock Ventures)
Hexagon Bio
Series BOct 2022$77M
Series UnknownSep 2021$61M
$190M
Co-investors: Alex Kolicich (8VC), Millie Ray (The Column Group), David Goeddel (The Column Group), Dusan Perovic (Two Sigma Ventures)
IconOVir Bio
Series AJan 2021$77M
$77M
Co-investors: David Schenkein (GV (Google Ventures)), Helen Kim (The Column Group)
Kronos Bio
Private EquityAug 2020$160M
Series AJul 2019$110M
$320M
Co-investors: David Schenkein (GV (Google Ventures)), Arie Belldegrun (Vida Ventures, LLC), Martin Alexander Gershon (Endeavor Venture Funds)
Vividion Therapeutics
Series BApr 2019$82M
$270M
Co-investors: Kristina Burow (ARCH Venture Partners), Tom Woiwode (Versant Ventures)
Arrakis Therapeutics
Series BApr 2019$75M
$110M
Co-investors: Krishna Yeshwant (GV (Google Ventures)), Colleen Cuffaro (Canaan Partners), Richard Gaster (venBio Partners)
Arvinas
Series CApr 2018$55M
$140M
Co-investors: Tim Shannon (Canaan Partners), Colleen Cuffaro (Canaan Partners), Stephen Squinto (OrbiMed), Kush Parmar (5am Ventures), Daniel Wagner (Connecticut Innovations), Liam Ratcliffe (New Leaf Venture Partners), Andrew Levin (RA Capital Management), Martin Alexander Gershon (Endeavor Venture Funds)
Managing Partner Nextech Invest Ltd.2017 - Present
Senior Adviser, SACC Life Science Acclerator SACC-NE (The Swedish-American Chamber of Commerce New England)Present
Board Observer Autolus TherapeuticsPresent
Board Member Vividion Therapeutics, Inc.Present
Board Member Kronos BioPresent
Board Observer Kinnate Biopharma Inc.Present
Managing Partner Nextech InvestPresent
Co-Founder and Managing Partner Juvia GroupPresent
Board Observer IDRx2022 - 2024
Board Member Hexagon Bio2021 - 2024
Board Member Flare Therapeutics2021 - 2024
Board Member IconOVir Bio2021 - 2024
Advisory Board Breakthrough Properties2020 - 2024
Board Member Arrakis Therapeutics2019 - 2024
Board Member A2 Biotherapeutics, Inc.2018 - 2024
Board Member Boundless Bio2021 - 2024
Board Member Vividion Therapeutics. Inc.2019 - 2021
Board Member Kronos Bio, Inc.2019 - 2021
Board Observer Kinnate Biopharma, Inc.2019 - 2021
Board Member Arvinas2018 - 2020
Board Observer Turning Point Therapeutics2018 - 2019
Board Observer Autolus Ltd.2017 - 2018
Co-Founder Relay Therapeutics2016 - 2017
Senior Investment Proffesional Third Rock Ventures2015 - 2017
Senior Adviser, SACC Life Science Acclerator Swedish American Chamber of Commerce - New England2013 - 2016
Co-Founder Syros Pharmaceuticals2013 - 2015
Postdoctoral Fellow Whitehead Institute2010 - 2013
PhD in Medical Sciences Karolinska Institutet2005 - 2010
Research Scientist AstraZeneca2002 - 2005
Conscript Officer and Boat Commander in the Swedish Royal Navy Special Forces Swedish Armed Forces1997 - 1999
Karolinska Institutet Doctor of Philosophy (Ph.D.) Medical Sciences
Anglia Ruskin University Bachelor's degree Biomedical Sciences
Sigtunaskolan Humanistiska Läroverket (SSHL) International Baccalaureate Natural Sciences
University of Cambridge Bachelor's degree Biomedical Sciences
Sign in with Google →
Sign in with Google →